Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
37,100
+2,650 (7.69%)
Apr 10, 2026, 3:30 PM KST
Market Cap1.09T -31.9%
Revenue (ttm)83.13B +53.4%
Net Income-47.39B
EPS-1,627.00
Shares Out29.28M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume216,445
Average Volume135,550
Open34,800
Previous Close34,450
Day's Range34,200 - 37,500
52-Week Range31,800 - 60,700
Beta1.25
RSI54.87
Earnings DateMay 14, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Sector Technology
Founded 2013
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2025, Lunit's revenue was 83.13 billion, an increase of 53.43% compared to the previous year's 54.18 billion. Losses were -47.39 billion, -42.69% less than in 2024.

Financial Statements